Lucid Diagnostics (LUCD) Set to Announce Quarterly Earnings on Tuesday

Lucid Diagnostics (NASDAQ:LUCD – Get Rating) will announce its earnings results before the market opens on Tuesday, May 16th. Investors interested in participating in the company’s conference call can do so using this link.

Lucid Diagnostics Trading Up 2.7 %

NASDAQ:LUCD opened at $1.53 on Friday. Lucid Diagnostics has a twelve month low of $1.11 and a twelve month high of $3.64. The company has a market cap of $66.39 million, a price-to-earnings ratio of -1.06 and a beta of 2.04. The stock has a fifty day simple moving average of $1.48 and a 200-day simple moving average of $1.54.

Institutional Trading of Lucid Diagnostics

Several institutional investors and hedge funds have recently made changes to their positions in LUCD. Vanguard Group Inc. raised its holdings in shares of Lucid Diagnostics by 11.3% in the third quarter. Vanguard Group Inc. now owns 319,366 shares of the company’s stock valued at $489,000 after acquiring an additional 32,305 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Lucid Diagnostics by 18.7% in the first quarter. BlackRock Inc. now owns 67,565 shares of the company’s stock valued at $227,000 after acquiring an additional 10,636 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Lucid Diagnostics in the first quarter valued at about $209,000. State Street Corp raised its holdings in shares of Lucid Diagnostics by 24.4% in the first quarter. State Street Corp now owns 56,693 shares of the company’s stock valued at $190,000 after acquiring an additional 11,121 shares in the last quarter. Finally, Verition Fund Management LLC grew its stake in Lucid Diagnostics by 29.2% in the second quarter. Verition Fund Management LLC now owns 46,709 shares of the company’s stock valued at $106,000 after purchasing an additional 10,543 shares during the last quarter. 5.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Needham & Company LLC reiterated a “buy” rating and set a $2.60 target price on shares of Lucid Diagnostics in a research report on Friday, April 21st.

Lucid Diagnostics Company Profile

(Get Rating)

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.